Published in Gene Therapy Weekly, June 28th, 1999
Treatment options for recurrent head and neck cancer are limited and usually highly toxic. W. Jarrad Goodwin and colleagues from Rhone-Poulen Rorer, Pennsylvania, suggest that gene therapy represents a novel therapeutic approach that could target the disease at the molecular and cellular levels.
The researchers conducted a phase II trial of a gene therapy for head and neck cancer using a replication-deficient adenovirus carrying the p53 gene (Ad5CMV-p53). Current results were presented at the 35th Annual Meeting of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.